The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model.

The efficacy of a recently engineered single chain recombinant equine follicle stimulating hormone (reFSH) was investigated in estrous cycling mares whose gonadotropins and follicular activity had been suppressed by concurrent treatment with progesterone and estradiol (P&E). Time of estrus was synchronized in 15 estrous cycling mares during the breeding season with prostaglandins F(2alpha) (PGF(2alpha)). The day after ovulation, mares were treated once daily with P&E for 14 days. Mares received a second injection of PGF(2alpha) on day 6 of the synchronized estrous cycle to induce luteolysis. On day 8 post-ovulation mares were randomly assigned to three groups: small dose reFSH-treatment group (0.5mg reFSH IV, twice daily); large dose reFSH-treatment group (0.85mg reFSH IV twice daily); control group (saline IV, twice daily). reFSH treatment occurred concurrently with the last week of P&E treatment. After a follicle or cohort of follicles reached 35mm in diameter, mares were injected with 0.75mg of recombinant equine luteinizing hormone (reLH) to induce ovulation. Post-treatment ovulation was assessed. Daily blood samples were collected for analysis of FSH, LH, estradiol, progesterone, and inhibin by radioimmunoassay (RIA). On the first day of reFSH/saline treatment, blood samples were collected periodically from 1h prior to treatment to 6h post-injection via an indwelling jugular catheter to determine acute changes in FSH concentrations. Monitoring of follicular activity, estrus, and ovulation was performed daily by utilizing a stallion and transrectal ultrasonography. A difference (por=35mm follicles (days 16-21) than controls. Mares treated with reFSH, at either dose, took less time (average: 2.95+/-0.42 days) to develop 2-3 times more pre-ovulatory follicles than control mares (7.8+/-0.51 days) (p

The efficacy of a single chain recombinant equine luteinizing hormone (reLH) in mares: induction of ovulation, hormone profiles, and inter-ovulatory intervals.

The objectives of this study were to determine the efficacy of recombinant equine luteinizing hormone (reLH) in shortening the time to ovulation in cycling mares and to determine the effects of treatment on endogenous hormones and inter-ovulatory intervals. In study 1, mares of light horse breeds (3-20 years) were treated with either a vehicle, various doses of reLH, or human chorionic gonadotropin (hCG). Cycling mares were examined by palpation and ultrasound per rectum daily or every 12h from the time of treatment to ovulation. In studies 2 and 3, jugular blood samples were collected daily or every 12h from the time of treatment to ovulation for analysis of LH, follicle stimulating hormone (FSH), estradiol-17beta (E(2)), and progesterone (P(4)) by radioimmunoassays (RIA). Increasing doses of reLH (0.3, 0.6, 0.75, and 0.9 mg) showed increasing effectiveness at inducing ovulation within 48 h of treatment. Treatments with the 0.75 and 0.9 mg doses of reLH resulted in 90% and 80% ovulation rates, which were similar to hCG treatment (85.7%). Except for the early rise in LH after treatment with 0.5, 0.65, and 1.0mg of reLH, hormone profiles appeared to be similar between control and treated cycles. Inter-ovulatory intervals were similar between control and treatment cycles. In conclusion, reLH is a reliable and effective ovulatory agent that does not significantly alter endogenous hormone profiles or affect inter-ovulatory intervals.

Evidence for a role of capillary pericytes in vascular growth of the developing ovine corpus luteum.

Because of rapid growth followed by spontaneous regression, the ovarian corpus luteum (CL) is an excellent model to study angiogenesis in vivo. To evaluate the expression of vascular endothelial growth factor (VEGF) protein during luteal development, ovaries were collected from FSH-stimulated ewes throughout the estrous cycle. VEGF was immunolocalized in tissue sections by using an affinity-purified antibody. VEGF protein localized exclusively to the thecal layer of preovulatory follicles, while the granulosa was devoid of staining. Associated with the periovulatory period was intense expression of VEGF by thecal cells at the basement membrane and subsequent invasion of the granulosa layers by these VEGF-positive cells immediately after ovulation. The early CL showed staining for VEGF in thecal-derived compartments, and strong staining for VEGF was also seen in cells within the granulosa-derived parenchymal lobules. Dual immunohistochemical localization of VEGF and smooth muscle cell alpha-actin indicated that the VEGF-positive cells were capillary pericytes or vascular smooth muscle cells. In another experiment, we quantified proliferation of endothelial cells and pericytes throughout luteal development. Pericytes represented a large proportion of the proliferating cells during the early luteal phase and then decreased dramatically. Perivascular cells, therefore, may play a critical role in angiogenesis that occurs during transformation of the follicle into the highly vascular CL of the sheep. As angiogenesis occurs only at the level of capillaries, and pericytes are integral members of these microvessels, regulation of pericytes may provide a novel mechanism for regulating luteal growth and tissue growth in general.

The position of the alpha and beta subunits in a single chain variant of human chorionic gonadotropin affects the heterodimeric interaction of the subunits and receptor-binding epitopes.

The glycoprotein hormone family represents a class of heterodimers, which include the placental hormone human chorionic gonadotropin (CG) and the anterior pituitary hormones follitropin, lutropin, and thyrotropin. They are composed of common alpha subunit and a hormone-specific beta subunit. Based on the CG crystal structure, it was suggested that the quaternary subunit interactions are crucial for biological activity. However, recent observations using single chain glycoprotein hormone analogs, where the beta and alpha subunits are linked (NH(2)-CGbeta-alpha; CGbetaalpha orientation), implied that the heterodimeric-like quaternary configuration is not a prerequisite for receptor binding/signal transduction. To study the heterodimeric alignment of the two subunit domains in a single chain and its role in the intracellular behavior and biological action of the hormone, a single chain CG variant was constructed in which the carboxyl terminus of alpha was fused to the CGbeta amino terminus (NH(2)-alpha-CGbeta; alphaCGbeta orientation). The secretion rate of alphaCGbeta from transfected Chinese hamster ovary cells was less than that seen for CGbetaalpha. The alphaCGbeta tether was not recognized by dimer-specific monoclonal antibodies and did not bind to lutropin/CG receptor. To define if one or both subunit domains were modified in alphaCGbeta, it was co-transfected with a monomeric alpha or CGbeta gene. In each case, alphaCGbeta/alpha and alphaCGbeta/CGbeta complexes were formed indicating that CG dimer-specific epitopes were established. The alphaCGbeta/alpha complex bound to receptor indicating that the beta domain in the alphaCGbeta tether was still functional. In contrast, no significant receptor binding of alphaCGbeta/CGbeta was observed indicating a major perturbation in the alpha domain. These results suggest that although dimeric-like determinants are present in both alphaCGbeta/alpha and alphaCGbeta/CGbeta complexes, the receptor binding determinants in the alpha domain of the tether are absent. These results show that generating heterodimeric determinants do not necessarily result in a bioactive molecule. Our data also indicate that the determinants for biological activity are distinct from those associated with intracellular behavior.

Nitric oxide is essential for optimal meiotic maturation of murine cumulus-oocyte complexes in vitro.

This study was conducted to determine whether endothelial-derived nitric oxide synthase (eNOS) affects meiotic maturation of mouse oocytes in vitro. Cumulus-oocyte complexes (COC) were isolated from ovarian follicles of 27-day-old PMSG-primed wildtype (WT), and eNOS-knockout (eNOS-KO) females, and cultured in drops of medium under oil at 37 degrees C for 16-18 hr. Experiment 1 was carried out to determine effects of eNOS deficiency on the ability of COC to mature in vitro. To determine whether acute synthesis of nitric oxide (NO) was required for oocyte maturation, COC collected from WT mice were cultured in medium without (control) or with different doses of N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NOS (exp. 2). To assess effects of NO deficiency on the kinetics of germinal vesicle breakdown (GVBD), COC from WT and eNOS-KO females were observed for 3.5 hr. COC from WT females were also incubated in medium without or with L-NAME (exp. 3 and 4). After the culture period, cumulus cells were removed, and oocytes were counted and classified as metaphase II (M II), metaphase I (M I) or showing atypical (degenerative) morphology. To determine viability and nuclear morphology of oocytes, they were stained with fluorescein diacetate or 4,6-diamidine-2'-phenylindole dihydrochloride, respectively. There were no differences in body weights but ovarian weights were lower in eNOS-KO mice compared with WT mice (P < 0.05). Ovaries from eNOS-KO mice contained fewer COC collected relative to WT mice (P < 0.01). Maturation of COC from eNOS-KO mice or WT oocytes treated with L-NAME resulted in a lower percentage of oocytes at M II stage (P < 0.01 and P < 0.05, respectively) and a higher percentage of oocytes at M I or atypical stages compared with those from WT (P < 0.01 and P < 0.05, respectively). Many oocytes that showed either an arrest in M I stage or abnormal morphology were not viable. Several oocytes in M II stage demonstrated abnormalities in distribution of maternal chromosomes. Our data demonstrate that eNOS-derived NO is a key modulator of oocyte meiotic maturation in vitro. These results support our previous observations in vivo and indicate that eNOS/NO has independent functions in both oocyte maturation and follicular/oocyte development.

Genetic fusion of an alpha-subunit gene to the follicle-stimulating hormone and chorionic gonadotropin-beta subunit genes: production of a bifunctional protein.

The human glycoprotein hormones, hCG, TSH, LH, and FSH, are composed of a common alpha-subunit assembled to a hormone-specific beta-subunit. The subunits combine noncovalently early in the secretory pathway and exist as heterodimers but not as multimers. LH/FSH are synthesized in the pituitary gonadotrophs, and several of the alpha-subunit sequences required for association with either the LHbeta or FSHbeta subunits are different. Thus, it is intriguing that no ternary complexes are observed for LH and FSH in vivo (e.g. two different beta-assembled to a single alpha-subunit). To examine whether the alpha-subunit can interact with more than one beta-subunit, and to study the conformational relationships between the ligand and the receptor, we constructed a vector encoding two tandemly arranged beta-subunits fused to a single alpha-subunit gene (FSHbeta-CGbeta-alpha). This approach permitted structure-function analyses of alpha/beta domain complexes without the possibility of subunit dissociation. We reported previously that the CGbeta or FSHbeta subunit gene can be genetically fused to the alpha-gene and the resulting single chains (CGbetaalpha and FSHbetaalpha, respectively) were biologically active. Here we demonstrate that a triple-domain single chain bearing the configuration FSHbeta-CGbeta-alpha is efficiently secreted from transfected Chinese hamster ovary (CHO) cells and exhibits high-affinity receptor binding to both FSH and LH/hCG receptors, comparable to the native heterodimers. These results indicate that the alpha-subunit can interact with each beta-subunit in the same complex and that an alpha-domain fused to a beta-domain can still interact with an additional beta-subunit. The data also demonstrate the remarkable flexibility of the receptor to accommodate the increased bulkiness of the triple-domain ligand. In addition, the formation of intrachain FSH- and CG-like complexes observed in a triple-domain single chain suggests that the alpha-subunit can resonate, i.e. shuttle between alpha-beta heterodimeric intermediates during the early stages of synthesis and accumulation in the endoplasmic reticulum. Such model compounds could be useful as substrates to generate a new class of analogs in which the ratio of the LH/FSH activity is varied. This could aid in the design of analogs that could be used to mimic the in vivo hormonal profiles.

Abnormal estrous cyclicity after disruption of endothelial and inducible nitric oxide synthase in mice.

The roles of nitric oxide (NO) and nitric oxide synthase (NOS) in reproduction were studied by examining the estrous cycle of wild-type (WT) mice, inducible NOS (iNOS)-, and endothelial NOS (eNOS)-knockout mice. We observed an average estrous cycle of 4.8 +/- 0.2 days in WT mice. While we observed no significant influence of iNOS deficiency on cycle length, eNOS-knockout females showed a significantly longer estrous cycle (6.6 +/- 0.6 days; p < 0.03) than WT females, due to an extension of diestrus (p < 0.03). There was no influence of iNOS deficiency on ovulation rate compared with that in WT females; however, eNOS-knockout mice showed a significant reduction (p < 0.05) in ovulatory efficiency relative to WT or iNOS-knockout females. In contrast to WT females, in which the highest level of estradiol (E2) was observed at 1500 h of proestrus, iNOS-knockout females reached a peak of E2 at 1830 h of proestrus. In eNOS-knockout females, the peak of E2 occurred at 1830 h, as in iNOS-knockout mice; however, E2 levels were 5-fold and 3-fold higher (p < 0.05) than levels observed in WT and iNOS-knockout females, respectively. There was no effect of genotype on the plasma LH concentrations at proestrus. On the first day of diestrus, eNOS-knockout females showed significantly higher plasma E2 and progesterone levels (p < 0.05) relative to WT and iNOS-knockout females. The dysfunction in cyclicity, ovulation rate, ovarian morphology, and steroidogenesis in eNOS-knockout female mice strongly supports the concept that eNOS/NO plays critical roles in ovulation and follicular development.

Inhibitors of nitric oxide synthase influence oocyte maturation in rats.

OBJECTIVE: To examine the effect of inhibiting nitric oxide synthase (NOS) on the number of ovulated oocytes and on oocyte meiotic maturation. METHODS: Female Sprague-Dawley rats (25 days old) were superovulated with a subcutaneous injection of 10 U pregnant mare's serum gonadotropin, followed 52 hours later by a subcutaneous injection of 10 U human chorionic gonadotropin (hCG). Three hours before and 3 hours after hCG injection, the rats were treated orally with the vehicle (0.5% methylcellulose) as the control or with either of two NOS inhibitors, N omega-nitro-L-arginine methyl ester (L-NAME) and L-N6-(1-iminoethyl)-lysine (L-NIL). The rats were killed 20 hours after hCG injection, and oocytes present in the oviduct were flushed, counted, and classified for stages of meiosis. In addition, ovarian oocytes (12 hours post-hCG) and ovulated oocytes were treated with an immunofluorescent stain for the presence of endothelial NOS (eNOS). RESULTS: Strong positive staining for eNOS was observed in the cytoplasm of ovarian and ovulated oocytes. Control rats ovulated an average 43.0 +/- 4.1 oocytes each, which was lowered with either L-NAME or L-NIL (23.8 +/- 4.3 and 23.5 +/- 4.0 oocytes per rat, respectively; P < .002). We observed that significantly fewer ovulated oocytes obtained from rats treated with NOS inhibitors were at metaphase II (P < .006), the normal stage of meiosis for unfertilized oocytes, and a significantly greater percentage of oocytes displayed atypical morphology as compared with control oocytes (P < .0001). CONCLUSION: Ovarian nitric oxide synthesis is required for maximal ovulation, and a lack of nitric oxide during the periovulatory period results in severe defects in oocyte maturation.

Gap junctional proteins, connexin 26, 32, and 43 in sheep ovaries throughout the estrous cycle.

Ovarian follicles from days 13, 14, 15, and 16 and corpora lutea (CL) from days 2, 4, 8, 12, and 15 of the estrous cycle were evaluated for the presence of connexins by immunohistochemistry. In addition, CL from days 5, 10, and 15 of the estrous cycle were used for immunofluorescent detection of Cx43 followed by image analysis, and for Western immunoblot. In all tissues, staining for all connexins appeared punctate, indicating the presence of assembled gap junctions. Cx26 was present in the ovarian surface epithelium, stroma, and blood vessels within the stroma and hilus, and in the CL. In healthy antral follicles, Cx26 was present only in the theca layer, whereas Cx43 was present in granulosa and theca layers. In the majority of atretic follicles, connexins were not detected, but in 13% of the atretic follicles, Cx43 was present in the theca layer. Cx32 was detected in the blood vessels of ovarian stroma and in the CL, and Cx43 was detected in the CL. Localization and/or expression of connexins depended on stage of luteal development. Western analysis demonstrated that expression of Cx32 in luteal tissues was similar across the estrous cycle. The area of positive staining for Cx43 and expression of Cx43 in luteal tissues decreased (p < 0.05) as the estrous cycle progressed. The pattern of expression of connexins indicates that gap junctional proteins may be important in the regulation of folliculogenesis and follicular atresia, as well as growth, differentiation, and regression of the CL.

The role of nitric oxide in oocyte meiotic maturation and ovulation: meiotic abnormalities of endothelial nitric oxide synthase knock-out mouse oocytes.

Evidence supports the involvement of nitric oxide (NO) in ovulation, steroidogenesis, and atresia-related apoptosis. This study was designed to investigate the role of endothelial nitric oxide synthase (eNOS)-derived NO in ovulation, oocyte meiotic maturation, and ovarian steroidogenesis using wild-type (WT) mice and mice in which the gene for eNOS had been deleted (eNOS knock-out). We observed that mature eNOS knock-out females have significantly fewer pups born in each litter and a higher mortality rate of pups than those born to heterozygote or WT females (P < 0.05). To determine the influence of eNOS deficiency on ovarian function, immature WT and eNOS knock-out mice were superovulated by injecting PMSG (5 IU) followed by an injection of hCG (5 IU, i.p.) 48 h later. To determine whether murine oocytes expressed eNOS before (0 and 8 h post-hCG) and after ovulation (16 h post-hCG). we performed immunofluorescent staining. Positive specific staining for eNOS was observed on the surface of ovarian and ovulated oocytes obtained from WT mice, but not on oocytes from eNOS knock-out mice. To determine the role of eNOS-derived NO in ovulation, ovulated oocytes were counted 16 h post-hCG. eNOS knock-out females showed a significant reduction (by 63%; P < 0.0001) in ovulatory efficiency compared with WT females. The reduction in the ovulation rate in eNOS-deficient mice compared with that in WT mice was also associated with a higher concentration of estradiol (P < 0.01) without significant changes in the plasma progesterone level. eNOS deficiency impaired not only ovulation, but also oocyte meiotic maturation. Ovulated oocytes were classified as being in one of the following stages of meiosis: metaphase I, metaphase II, or showing atypical (degenerative) morphology. We observed that fewer oocytes from eNOS knock-out mice had entered metaphase II of meiosis, and a greater percentage remained in metaphase I or were atypical (P < 0.002) relative to those in WT mice. Furthermore, many oocytes that showed either a delay in meiotic maturation or abnormal morphology were undergoing cell death. Our results support a role for NO in the ovulatory process. The ovarian defects observed in the eNOS knock-out mice suggest that eNOS-derived NO is a modulator of oocyte meiotic maturation.

Gene expression of nitric oxide synthase in cultured human term placental trophoblast during in vitro differentiation.

The human placental syncytiotrophoblast is derived from differentiating cytotrophoblasts and is in contact with maternal blood. This endothelial function positions the trophoblast to regulate maternal-fetal exchange and to influence circulatory dynamics through paracrine interactions in the placenta. Two isoforms of nitric oxide synthase (NOS) are expressed in placenta, and northern analysis, reverse transcription-polymerase chain reaction (RT-PCR), and immunocytochemistry were used to correlate expression of the type II, inducible NOS (iNOS) and the type III, endothelial NOS (eNOS) with state of differentiation in cultured trophoblast from term placentae. It was also tested whether cytokines known to induce NOS in other cell systems would induce iNOS in human trophoblast. The mRNA for eNOS was detected by RT-PCR, but not by Northern analysis, in cultures grown for 24 h when cytotrophoblasts were dominant. In contrast, eNOS mRNA was abundant in cultures grown for 72 h when syncytiotrophoblast was present. Immunocytochemical staining for eNOS protein showed specific fluorescence in a few cells in cultures at 24 h, but the vast majority of cells expressed eNOS at 72 h. The iNOS isoform was expressed neither basally in any trophoblast culture nor was this isoform induced in cultures exposed to interleukin-1, tumour necrosis factor-alpha, interferon-gamma and lipopolysaccharide. The in vitro pattern of trophoblast eNOS expression models the in vivo pattern of eNOS expression described for villous trophoblast. The results suggest that eNOS plays a role in human trophoblast differentiation and function.

Cellular proliferation and fibroblast growth factors in the corpus luteum during early pregnancy in ewes.

To determine the relationship between cellular proliferation and the presence of FGF-1 and FGF-2 in the ovine corpus luteum (CL) during early pregnancy, ewes received an intravenous injection of bromodeoxyuridine (BrdU) 1 h before slaughter (n = 3/day) on day 12 after estrus (nonpregnant) or on days 12, 18, 24 or 30 after mating (pregnant). The labeling index (LI; number of BrdU-labeled nuclei expressed as a percentage of total nuclei) of each CL was determined by immunohistochemistry and subsequent image analysis. FGF-1 and FGF-2 were immunolocalized by using specific antibodies, and indirect immunoperoxidase detection. Moreover, FGF-2 was immunolocalized by using a primary antibody and fluorescein isothiocyanate (FITC)-labeled secondary antibody, and immunofluorescence was quantified by using an interactive laser cytometer and image analysis. Results demonstrated that the LI was similar for CL of nonpregnant and pregnant ewes on day 12 (4.27 +/- 0.23 vs 5.10 +/- 0.14%) and decreased (P < 0.05) from days 12-30 of pregnancy (2.73 +/- 0.08, 2.02 +/- 0.09 and 1.70 +/- 0.04% on days 18, 24 and 30, respectively). FGF-1 was present in the cytoplasm of large and a few small parenchymal luteal cells, and the distribution and intensity of staining was similar for nonpregnant and pregnant ewes on day 12 as well as across days of pregnancy. In contrast, FGF-2 immunoreactivity was present only in luteal nonparenchymal cells and interstitial areas and was greater (P < 0.05) for pregnant than nonpregnant CL on day 12 (2.34 +/- 0.12 vs 0.14 +/- 0.01%). Although FGF-2 immunoreactivity decreased (P < 0.01) from days 12-30 of pregnancy (0.70 +/- 0.04, 0.22 +/- 0.01 and 0.06 +/- 0.02% on days 18, 24, and 30, respectively), it was highly correlated (r = 0.99, P < 0.01) with luteal LI. We therefore suggest that FGF, and especially FGF-2, play a role in luteal cell proliferation or turnover during early pregnancy, and may thereby contribute to the maintenance of luteal function, which is critical for the successful establishment of pregnancy.

Hormonal regulation of nitric oxide synthases and their cell-specific expression during follicular development in the rat ovary.

Nitric oxide (NO) has emerged as a novel regulator of several ovarian events, such as ovulation, steroidogenesis, and apoptotic cell death. The NO synthases (NOS) are a family of enzymes that catalyze the oxidation of L-arginine to NO and L-citrulline. The purpose of the present study was to localize NOS isoforms in the rat ovary and to examine their hormonal regulation. We conducted immunohistochemistry and Western blot analysis using isoform-specific antibodies against brain NOS, endothelial NOS (eNOS), and inducible NOS (iNOS). Immature rats were superovulated by injecting PMSG (10 I.U. s.c.) followed by an injection of human CG (hCG; 10 I.U. s.c.) 48 h later. Ovaries were obtained from control rats (no PMSG), 24 h and 48 h after PMSG treatment and 2 h, 8 h, 12 h, 20 h or 6 days and 10 days after hCG injection (n = 3-5 rats/group). Rat ovaries were clearly devoid of brain NOS staining at any of the time points studied. In control ovaries, eNOS was detected in the theca cell layer, ovarian stroma, and on the surface of oocytes. During follicular development, eNOS staining was still expressed in the theca cell layer and was also present in mural granulosa cells. After ovulation, homogenous eNOS staining was observed within cells of the corpus luteum (CL). Western blots of ovarian homogenates demonstrated that during PMSG-induced follicle growth, eNOS levels increased by 2.5-fold relative to control rats (P < 0.05). eNOS levels were further increased 12 h and 20 h after hCG injection (5-fold and 7-fold, respectively, relative to control; P < 0.05). The greatest amount of eNOS was observed in ovaries 10 days after hCG injection (15-fold relative to control; P < 0.05). We also detected expression of iNOS in the ovary, but the pattern and cell-specific staining differed from that observed for eNOS. In immature ovaries and during follicular development, iNOS staining was found within the theca cell layer and stroma. After ovulation, iNOS staining was present only in the external layers of the developing CL, but in the degenerating CL (10 days post-hCG), strong staining in nonparenchymal cells was observed within the entire CL. Western blots showed no changes in levels of ovarian iNOS protein during follicular development, but a significant increase (6-fold relative to control; P < 0.05) was observed after an ovulatory dose of hCG. The highest level of iNOS was observed in ovaries 10 days after hCG injection (10-fold relative to control; P < 0.05). Our data demonstrate that ovarian eNOS and iNOS show distinct cell-specific expression patterns and are differentially regulated during follicular and luteal development.

Effects of gonadotropin treatment and withdrawal on follicular growth, cell proliferation, and atresia in ewes.

To determine the effects of FSH-P treatment and subsequent withdrawal on follicular growth, cell proliferation, and atresia, ewes (n = 4 ewes/treatment group) received twice daily injections of saline or FSH-P beginning on Day 13 of the estrous cycle (length of the estrous cycle = 16.5 days) and were slaughtered after 0, 48, or 72 h of treatment (i.e., on Days 13, 15, or 16). Some treatment groups received FSH-P from Day 13 until slaughter (FSH-P-treated), whereas some received FSH-P for 24-48 h followed by saline for 24-48 h (FSH-P withdrawal). All ewes received an i.v. injection of bromodeoxyuridine (BrdU, a thymidine analogue) 1 h before slaughter. For both ovaries from each ewe, the number and surface diameter of all visible antral follicles were determined, and antral follicles were classified as small (< or = 3 mm), medium (> 3 mm to < or = 6 mm), or large (> 6 mm). As an index of the rate of cell proliferation, BrdU was immunolocalized in paraffin-embedded tissue sections, and the labeling index (LI; BrdU-labeled nuclei as a percentage of total nuclei) was determined for granulosa and thecal cells of nonatretic and early atretic antral follicles of known diameter. Follicular status (atretic vs. nonatretic) was evaluated morphologically. Moreover, the presence of apoptosis was detected in situ by using the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling method. For untreated and saline-treated ewes, the number of small follicles per ewe increased (p < 0.01) from Day 13 to Day 15, then decreased again on Day 16, whereas numbers of medium and large follicles did not differ across days. Compared with saline-treated ewes, ewes receiving FSH-P from Day 13 until slaughter had fewer (p < 0.05) small but more (p < 0.05) medium and large follicles. Compared with FSH-P-treated ewes, FSH-P withdrawal resulted in fewer (p < 0.05) medium and large but more (p < 0.05) small follicles. Across all follicular size classes, granulosa and thecal cell LI of nonatretic follicles was decreased (p < 0.05) by FSH-P withdrawal compared with FSH-P treatment. Additionally, across all follicular size classes, FSH-P withdrawal increased (p < 0.01) the percentage of follicles that were atretic compared with saline or FSH-P treatment. Histochemical staining of early and advanced atretic follicles showed that granulosa cells are the predominant site of cell death (apoptosis) during follicular atresia. Thus, compared with continuous FSH-P treatment, withdrawal of FSH-P resulted in decreased numbers of medium and large follicles, decreased proliferation of follicular cells, and an increased incidence of atresia associated with granulosa cell death. This model should prove useful for studying the mechanisms regulating follicular growth and atresia in ewes.

Nitric oxide decreases estradiol synthesis of rat luteinized ovarian cells: possible role for nitric oxide in functional luteal regression.

This study was designed to examine the synthesis and function of nitric oxide during follicular development and luteinization in the rat ovary. Cells were obtained from hypophysectomized diethylstilbestrol-implanted immature female rats subjected to several hormonal regimens that resulted in preantral, Graafian, ovulatory, atretic, or luteinized ovaries. Cells obtained from ovaries at all stages of follicular development synthesized nitric oxide in a linear manner over time. The basal production of nitric oxide was 6- to 14-fold higher (P < 0.009) in cells obtained from luteinized ovaries than that in cells obtained from ovaries at all other developmental stages. Inhibiting endogenous nitric oxide synthesis in cells obtained from luteinized ovaries resulted in a 3-fold increase (P < 0.007) in the estradiol level without affecting progesterone synthesis. We used isoform-specific antisera to determine the cellular location and isoform(s) of nitric oxide synthase expressed in our cell culture system and in the luteinized ovary in vivo. Positive immunofluorescent staining for both the endothelial and inducible isoforms was observed in separate cell types. Immunoblotting experiments also showed that luteinized ovaries express the endothelial and inducible isoforms of nitric oxide synthase. Nitric oxide synthesis inhibits estradiol synthesis in vitro. We suggest that nitric oxide participates in functional luteal regression by inhibiting steroidogenesis.

Gap junctional protein connexin 43 in bovine corpora lutea throughout the estrous cycle.

The present study examined the pattern of expression of the gap junctional protein connexin 43 (Cx43) in bovine corpora lutea (CL) during growth, differentiation, and regression. CL from the early (n = 6), mid- (n = 6), and late (n = 6) luteal phases of the estrous cycle were weighed and divided into several portions. One portion of each CL was frozen in liquid nitrogen for evaluation of protein, DNA, progesterone, and presence of Cx43 by Western immunoblot analysis; another portion was frozen in liquid propane for immunofluorescent staining of Cx43. An additional portion of each CL was dispersed, and the luteal cells were cultured for 2 days, fixed, and used for immunofluorescent staining of Cx43. Weights and DNA, protein, and progesterone contents of CL increased (p < 0.05) from the early to mid-luteal phases and then decreased (p < 0.05) from the mid- to late luteal phases. The ratio of protein to DNA was similar in the early and mid-luteal phases and then decreased (p < 0.05) to the late luteal phase. Western immunoblot analysis revealed bands at 43 kDa that differed in volume (evaluated by densitometry); the early luteal phase volume was greater (p < 0.05) than that at the mid-luteal phase, which was greater (p < 0.05) than that at the late luteal phase. Immunofluorescent staining demonstrated that Cx43 was present in luteal tissues and cultured luteal cells throughout the estrous cycle, and the area of positive staining decreased (p < 0.05) as the estrous cycle progressed. Staining for Cx43 was punctate and localized to the cellular borders. Thus, levels of Cx43 in bovine CL are greatest early in the estrous cycle and are least late in the estrous cycle. These data demonstrate that gap junctions may be important for regulation of luteal growth, differentiation, and regression in the cow.

Immunohistochemical localization of 3 beta-hydroxysteroid dehydrogenase and P450 17 alpha-hydroxylase during follicular and luteal development in pigs, sheep, and cows.

Follicular and luteal morphology and steroidogenic function were investigated by immunohistochemistry for cytochrome P450 17 alpha-hydroxylase (P450c17) and 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) during the estrous cycle in pigs, sheep, and cows. The theca interna of all species expressed P450c17 during follicular development. In the pig, this constituted a continuous layer of cells around the follicle, but a sheath of cells lining the basement membrane appeared not to express P450c17. Neither was expression of P450c17 in ovine and bovine follicles uniform throughout the theca interna. In these two species, a beaded appearance was given by P450c17, since it was expressed in some regions but not in others. Therefore, staining for P450c17 defined functional sub-populations of cells within the theca interna of pigs, sheep, and cows. Ovulation was associated with a decrease in P450c17 in all species, but some expression persisted in theca-derived cells of developing and mature porcine CL. Expression of 3 beta-HSD in the preovulatory follicle was confined to the theca of the pig and sheep; in contrast, in the cow, it was highest in the granulosa. In general, 3 beta-HSD expression appeared to be greater in porcine than ovine or bovine follicles, the physiological relevance of which is discussed. Porcine and ovine theca continued to express 3 beta-HSD after ovulation, and granulosa-derived cells increased their 3 beta-HSD expression markedly as they luteinized in all three species. During early luteal development in pigs and sheep, theca-derived cells with high 3 beta-HSD encircled luteal lobules, but these cells appeared throughout the parenchyma of the mature CL. Luteal regression in sheep and cows was typified by the loss of many cells expressing 3 beta-HSD, whereas others, adjacent to them, appeared to be intact without loss of enzyme expression. These data further define differences in steroidogenesis during follicular and luteal development among the pig, sheep, and cow.

Proliferation and progesterone production of ovine luteal cells from several stages of the estrous cycle: effects of fibroblast growth factors and luteinizing hormone.

This study was conducted to evaluate the effects of fibroblast growth factor 1 (FGF-1), fibroblast growth factor 2 (FGF-2), or luteinizing hormone (LH) on proliferation and progesterone secretion of ovine luteal cells from days 5, 10, or 15 after estrus (estrus = day 0; n = 4 or 5 ewes/day). After enzymatic dispersion, luteal cells were incubated in the presence or absence of various doses of FGF-1, FGF-2, LH, or fetal bovine serum (FBS) (positive control) in serum-free media for 7 days in 24-well plates. Cells were counted on day 7 of culture and media analyzed for progesterone concentration. For all treatments, maximal effects (Emax) and dissociation constants (KD) were calculated. In addition, luteal cells were cultured in eight-chamber slides and treated as above, but on day 7 of culture cells were fixed and stained for the presence of 3beta-hydroxy-delta 5-steroid dehydrogenase (3beta HSD). The number of steroidogenic (3beta HSD positive) cells per unit area was counted for control cultures (no treatment) and cultures treated with the most effective doses of FGF-1, FGF-2, LH, OR FBS in proliferation and (or) progesterone assays. FGF-1, FGF-2, AND FBS stimulated (p < 0.05) proliferation of luteal cells from all stages of luteal development in a dose-dependent manner. In addition, LH increased (p < 0.01) the number of 3beta HSD-positive cells across all stages of luteal development. Moreover, LH and FBS increased (p < 0.05) progesterone secretion by luteal cells from all stages in a dose-responsive manner, but the effects of FGF-1 and FGF-2 were variable. For proliferation, the Emax of all factors was greatest (p < 0.01) on day 5, whereas the KD values were similar across days of the estrous cycle. For progesterone production, the Emax and KD of LH and FBS were similar and did not differ across the estrous cycle. These data demonstrate the luteal cells from the early luteal phase of the estrous cycle exhibit the greatest ability to proliferate and (or) increase their progesterone secretion in response to FGF-1, FGF-2, LH, or FBS. In addition, although LH does not affect the total number of luteal cells in culture, it does increase the number of steroidogenic cells. These data indicate that in addition to LH, fibroblast growth factors may be involved in regulation of luteal growth and differentiation in ewes.

Size, number, cellular proliferation, and atresia of gonadotropin-induced follicles in ewes.

To determine the effect of exogenous gonadotropin on size, number, cellular proliferation, and atresia of follicles, ewes (n = 3-5/treatment/day) received an injection of vehicle or FSH-P (a pituitary extract) twice daily on Days 13, 14, and 15 (5, 4, and 3 mg FSH-P/injection, respectively; Day 0 = estrus) and were slaughtered on Days 14, 15, or 16 (i.e., after 24, 48, or 72 h of FSH-P treatment, respectively). An additional group of ewes (Day 13 control) received no treatment and were slaughtered on Day 13. All ewes received an i.v. injection of bromodeoxyuridine (BrdU, a thymidine analog; 5 mg/kg-1 BW) 1 h before slaughter. For both ovaries from each ewe, number and surface diameter of all visible follicles were recorded, and antral follicles were classified as small (< or = 3 mm), medium (> 3 mm to < or = 6 mm), or large (> 6 mm). To evaluate rate of proliferation of follicular cells, ovaries were fixed by perfusion with Carnoy's solution, and BrdU was immunolocalized in paraffin-embedded sections by use of a specific primary antibody and indirect immunoperoxidase detection. As an index of the rate of cellular proliferation, labeling index (LI: number of BrdU-labeled nuclei expressed as a percentage of total nuclei) of granulosa and thecal cells was determined by image analysis of antral follicles of known diameter. Follicular status (atretic vs. nonatretic) also was evaluated morphologically by using the histological sections. After 24 h of treatment (i.e., on Day 14), FSH-P-treated ewes had an increased (p < 0.01) number of medium follicles compared with vehicle-treated ewes.(ABSTRACT TRUNCATED AT 250 WORDS)

Growth and cellular proliferation of ovine corpora lutea throughout the estrous cycle.

This study was conducted to determine the rates of growth and cellular proliferation of ovine corpora lutea (CL) throughout the estrous cycle. To determine the cellular labeling index (LI), ewes received an iv injection of bromodeoxyuridine (BrdU) 1 h before death on days 2, 4, 8, 12, or 15 (day 0 = estrus; n = 6-12 ewes/day). At death, CL were weighed, and samples of each were fixed in Carnoy's solution or frozen until analyzed for DNA, protein, and progesterone contents. Nuclear incorporation of BrdU was determined in paraffin-embedded tissue sections by using a primary antibody against BrdU and a fluorescent (fluorescein isothiocyanate-labeled) secondary antibody, and sections were counterstained with propidium iodide (a nuclear stain). The labeling index (BrdU-labeled nuclei as a proportion of propidium iodide-labeled nuclei) of each CL was determined by using dual channel interactive laser cytometry and image analysis. Moreover, BrdU and 3 beta-hydroxysteroid dehydrogenase (a marker for steroidogenic cells) or BrdU and factor VIII (a marker for endothelial cells) were immunolocalized in tissue sections by using double immunohistochemical or dual immunofluorescent staining, respectively. Results demonstrated that cellular proliferation was greatest (LI, 34.1 +/- 2.1%) on day 2 and decreased (P < 0.01) through day 15 (LI, 0.7 +/- 0.1%) of the estrous cycle. The results of the immunohistochemical studies provide evidence that both parenchymal (steroidogenic) and nonparenchymal (e.g. endothelial, fibroblastic) luteal cells proliferated throughout the ovine estrous cycle. Conversely, from days 2-12 of the estrous cycle, fresh weight and DNA content of CL increased linearly (P < 0.01; 8- and 10-fold, respectively), then decreased (P < 0.02) from days 12-15. Ratios of protein/DNA on days 2, 4, and 8 were similar and were greater (P < 0.02) than those on days 12 and 15, which also were similar. These data demonstrate that growth of the ovine CL is extremely rapid, linear from days 2-12, and primarily due to hyperplasia. In addition, the high rate of cellular proliferation is associated primarily with nonsteroidogenic cells, a large proportion of which appear to be endothelial cells. Data such as these will enable us to determine the factors that are important in regulating luteal growth and development in normal and pathological conditions.